Want to see IN:TAKE full AI Analyst Report?
TAKE Stock Chart & Stats
₹20.76
₹0.05(0.24%)
At close: 4:00 PM EDT
₹20.76
₹0.05(0.24%)
Day’s Range― - ―
52-Week Range₹10.35 - ₹49.90
Previous CloseN/A
Volume250.59K
Average Volume (3M)94.04K
Market Cap
₹2.29B
Enterprise Value₹5.86K
Total Cash (Recent Filing)₹2.80M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)17.9
Beta1.23
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.03%
Share Statistics
EPS (TTM)0.87
Shares Outstanding147,934,000
10 Day Avg. Volume56,726
30 Day Avg. Volume94,042
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Life-sciences SpecializationSpecialization in regulated life-sciences markets gives TAKE a defined domain position and aligns its services with complex clinical, regulatory, quality, and commercial processes. This focus can support repeat client relationships because customers often value industry knowledge, validation capability, and process continuity.
Debt-free Balance SheetReported zero debt in the two latest annual periods materially reduces interest obligations and refinancing exposure. This provides greater financial flexibility than the company’s earlier leveraged position and leaves more capacity to preserve liquidity, support operations, or invest in its life-sciences service platform.
Equity RecoveryThe return to positive stockholders’ equity indicates that the balance sheet has repaired from the FY2024 impairment. Although the recovery does not remove historical volatility, a positive capital base improves resilience, reduces the severity of balance-sheet constraints, and supports continued operation without relying on debt.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow alongside reported net income signals weak earnings-to-cash conversion. If this pattern continues, TAKE may have less internally generated funding for investment and working needs, while relying more heavily on balance-sheet resources to sustain the business through operating volatility.
Weak Core ProfitabilityNegative gross and operating profit indicate that the core business was not covering its direct and operating costs in FY2026. Positive net income therefore appears disconnected from operating performance, weakening confidence in recurring earnings quality and making future profitability more dependent on improvements in the underlying business.
Highly Volatile Operating ResultsThe sharp revenue swings and repeated historical losses point to an unstable earnings base rather than predictable compounding. Such volatility makes planning and resource allocation harder, limits confidence in sustainable margins, and increases the risk that a reported rebound will not translate into durable operating performance.
TAKE Solutions Limited News
TAKE FAQ
What was TAKE Solutions Limited’s price range in the past 12 months?
TAKE Solutions Limited lowest stock price was ₹10.35 and its highest was ₹49.90 in the past 12 months.
What is TAKE Solutions Limited’s market cap?
TAKE Solutions Limited’s market cap is ₹2.29B.
When is TAKE Solutions Limited’s upcoming earnings report date?
TAKE Solutions Limited’s upcoming earnings report date is Nov 14, 2026 which is in 46 days.
How were TAKE Solutions Limited’s earnings last quarter?
TAKE Solutions Limited released its earnings results on Aug 11, 2026. The company reported ₹0.072 earnings per share for the quarter.
Is TAKE Solutions Limited overvalued?
According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued.
Does TAKE Solutions Limited pay dividends?
TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of 1.03%. See more information on TAKE Solutions Limited dividends here
What is TAKE Solutions Limited’s EPS estimate?
TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TAKE Solutions Limited have?
TAKE Solutions Limited has 147,934,000 shares outstanding.
What happened to TAKE Solutions Limited’s price movement after its last earnings report?
TAKE Solutions Limited reported an EPS of ₹0.072 in its last earnings report. Following the earnings report the stock price went up 1.174%.
Which hedge fund is a major shareholder of TAKE Solutions Limited?
Currently, no hedge funds are holding shares in IN:TAKE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TAKE Solutions Limited
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―